首页> 中文期刊> 《中国美容医学》 >上直肌联合上睑提肌腱膜缩短术治疗中重度上睑下垂

上直肌联合上睑提肌腱膜缩短术治疗中重度上睑下垂

         

摘要

ObjectiveTo consider the efifcacy of superior rectus muscle combined with levator palpebrae superioris shortening in the treatment of blepharoptosis.Methods We analyzed 74 patients' medical record information who adopted superior rectus muscle combined with levator palpebrae superioris shortening in our hospital from January 2014 to May 2017. And observed the clinical efifcacy and postoperative complications of the patients.Results In the 74 cases, overcorrection in 2 cases, one case of undercorrection, 3 cases with post-operative upper eyelid swelling relieved after physiotherapy and wound dressing 5d, upper eyelid hematoma in one case, one case of hypophasis. The average follow-up of 10 months, all of them no recurrence. Conclusion Superior rectus muscle combined with levator palpebrae superioris shortening in the treatment of blepharoptosis is safe and effective, worthy of promotion.%目的:探讨上直肌联合上睑提肌腱膜缩短术矫正中重度上睑下垂的临床疗效.方法:回顾性统计分析2014年1月-2017年5月于本院行上直肌联合上睑提肌腱膜缩短术的74例中重度上睑下垂患者的病例资料,观察患者的临床疗效及术后并发症发生情况.结果:本组74例患者,过度矫正2例,矫正不足1例;术后上眼睑肿胀3例,给予换药、理疗5d后缓解;上眼睑血肿1例;眼睑闭合不全1例.平均随访10个月,均无复发.结论:上直肌联合上睑提肌腱膜缩短术治疗中重度上睑下垂疗效确切,并发症少,值得临床推广.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号